Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. (Q46375220)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

49375

dasatinib monohydrate

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

C Mol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

C Hayford

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

S Ghaem-Maghami

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

N J Dibb

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

11 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

590-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18784745%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.237

14 January 2020

exact match

0 references

cites work

Tumour-educated macrophages promote tumour progression and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

M-CSF mediates TNF-induced inflammatory osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Dasatinib suppresses in vitro natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

7 January 2021

Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

7 January 2021

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

7 January 2021

Long-term imatinib therapy promotes bone formation in CML patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.237

7 January 2021